DCF Advisers’s Amgen AMGN Stock Holding History

DCF Advisers’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,000	Closed	-$806K	–	86
2023 Q3	$806K	Buy	+3,000	New	+$749K	0.44%	49

Other funds holding AMGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

DCF Advisers's AMGN Position: Q2 2026 in Review

DCF Advisers reduced its Amgen (AMGN) stake by 13% in Q2 2026, selling an estimated $257K and leaving 5,250 shares worth $1.9M. The position accounts for 0.34% of the portfolio, ranked #50.

DCF Advisers first reported a position in AMGN in Q4 2019 and has held it in 23 quarters since. The position peaked at $4.42M in Q4 2025. 3,153 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

DCF Advisers held 5,250 shares of Amgen worth $1.9M as of Q2 2026.
DCF Advisers sold 750 Amgen shares in Q2 2026, an estimated $257K.
Amgen made up 0.34% of DCF Advisers's portfolio in Q2 2026, its #50 holding.
DCF Advisers first reported a position in Amgen in Q4 2019 and has held it in 23 quarters since.
DCF Advisers's Amgen position peaked at $4.42M in Q4 2025.
3,153 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.